Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Image caption, STEP 2: Repeat this four times ... Image caption, You can see that the coins in this formation make a parabola (a u-shaped symmetrical curve). You can see this clearly if you ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...

As a treatment administered only once, it carries an enormous $2.2 million list price. Vertex and CRISPR Therapeutics haven't started recording significant sales of Casgevy yet, but it could start ...

The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...

VX-522: The multiple ascending dose (MAD) portion of the Phase 1/2 study of VX-522 is underway, with data expected in the first half of 2025. VX-522 is a CFTR mRNA therapeutic that Vertex is ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...

Over the last 30 days, this estimate has changed -2%. For the next fiscal year, the consensus earnings estimate of $18.26 indicates a change of +4,247.1% from what Vertex is expected to report a ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...